...
首页> 外文期刊>BJU international >Biparametric vs multiparametric prostate magnetic resonance imaging for the detection of prostate cancer in treatment‐na?ve patients: a diagnostic test accuracy systematic review and meta‐analysis
【24h】

Biparametric vs multiparametric prostate magnetic resonance imaging for the detection of prostate cancer in treatment‐na?ve patients: a diagnostic test accuracy systematic review and meta‐analysis

机译:Biparametric VS Multiparametric前列腺磁共振成像用于治疗治疗患者前列腺癌:诊断测试精度系统综述和荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Objective To perform a diagnostic test accuracy (DTA) systematic review and meta‐analysis comparing multiparametric (diffusion‐weighted imaging [DWI], T2‐weighted imaging [T2WI], and dynamic contrast‐enhanced [DCE] imaging) magnetic resonance imaging (mpMRI) and biparametric (DWI and T2WI) MRI (bpMRI) in detecting prostate cancer in treatment‐na?ve patients. Methods The Medical Literature Analysis and Retrieval System Online (MEDLINE) and Excerpta Medica dataBASE (EMBASE) were searched to identify relevant studies published after 1 January 2012. Articles underwent title, abstract, and full‐text screening. Inclusion criteria consisted of patients with suspected prostate cancer, bpMRI and/or mpMRI as the index test(s), histopathology as the reference standard, and a DTA outcome measure. Methodological and DTA data were extracted. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)‐2 tool. DTA metrics were pooled using bivariate random‐effects meta‐analysis. Subgroup analysis was conducted to assess for heterogeneity. Results From an initial 3502 studies, 31 studies reporting on 9480 patients (4296 with prostate cancer) met the inclusion criteria for the meta‐analysis; 25 studies reported on mpMRI (7000 patients, 2954 with prostate cancer) and 12 studies reported on bpMRI DTA (2716 patients, 1477 with prostate cancer). Pooled summary statistics demonstrated no significant difference for sensitivity (mpMRI: 86%, 95% confidence interval [CI] 81–90; bpMRI: 90%, 95% CI 83–94) or specificity (mpMRI: 73%, 95% CI 64–81; bpMRI: 70%, 95% CI 42–83). The summary receiver operating characteristic curves were comparable for mpMRI (0.87) and bpMRI (0.90). Conclusions No significant difference in DTA was found between mpMRI and bpMRI in diagnosing prostate cancer in treatment‐na?ve patients. Study heterogeneity warrants cautious interpretation of the results. With replication of our findings in dedicated validation studies, bpMRI may serve as a faster, cheaper, gadolinium‐free alternative to mpMRI.
机译:目的探讨诊断测试精度(DTA)系统审查和Meta分析比较Multiparametric(扩散加权成像[DWI],T2加权成像[T2WI]和动态对比度增强的[DCE]磁共振成像(MPMRI )和Biparametric(DWI和T2WI)MRI(BPMRI)检测治疗中的前列腺癌患者。方法检测医学文献分析和检索系统(MEDLINE)和EXCERPTA MEDICA数据库(EMBASE)识别2012年1月1日之后发表的相关研究。作品接受了标题,摘要和全文筛选。纳入标准由疑似前列腺癌,BPMRI和/或MPMRI作为指数试验,组织病理学作为参考标准的患者组成,以及DTA结果测量。提取方法和DTA数据。使用诊断准确性研究(Quadas)-2工具的质量评估评估偏差风险。使用双变量随机效应元分析汇集了DTA指标。进行亚组分析以评估异质性。初始3502项研究结果,31项研究报告报告9480名患者(带前列腺癌4296例)符合荟萃分析的纳入标准; 25例研究报告了MPMRI(7000名患者,2954例,前列腺癌)和12项研究报告于BPMRI DTA(2716名患者,1477名,前列腺癌)。汇总的概要统计证明对敏感性没有显着差异(MPMRI:86%,95%置信区间[CI] 81-90; BPMRI:90%,95%CI 83-94)或特异性(MPMRI:73%,95%CI 64 -81; BPMRI:70%,95%CI 42-83)。概述接收器操作特性曲线对于MPMRI(0.87)和BPMRI(0.90)相当。结论MPMRI与BPMRI之间没有显着差异在治疗治疗患者中的前列腺癌之间。研究异质性认证对结果的谨慎对策。通过在专用验证研究中复制我们的调查结果,BPMRI可以作为MPMRI更快,更便宜地替代,无钆的替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号